×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AUPH – aurinia pharmaceuticals inc - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AUPH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/2
07:36 pm
auph
Should Aurinia's Surging 2025 Earnings and Upbeat 2026 Outlook Require Action From Aurinia (AUPH) Investors? [Yahoo! Finance]
Low
Report
Should Aurinia's Surging 2025 Earnings and Upbeat 2026 Outlook Require Action From Aurinia (AUPH) Investors? [Yahoo! Finance]
3/1
04:40 am
auph
Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025 [Yahoo! Finance]
Low
Report
Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025 [Yahoo! Finance]
2/26
12:21 pm
auph
Aurinia Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Aurinia Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
06:23 am
auph
Aurinia: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Aurinia: Q4 Earnings Snapshot [Yahoo! Finance]
2/26
06:19 am
auph
Aurinia Pharma GAAP EPS of $1.53 beats by $1.31, revenue of $77.1M beats by $2.4M [Seeking Alpha]
Low
Report
Aurinia Pharma GAAP EPS of $1.53 beats by $1.31, revenue of $77.1M beats by $2.4M [Seeking Alpha]
2/26
06:00 am
auph
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
Low
Report
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
2/19
06:17 am
auph
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 [Yahoo! Finance]
Low
Report
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 [Yahoo! Finance]
2/19
06:00 am
auph
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
Low
Report
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2026
06:00 am
auph
aurinia pharmaceuticals inc - common shares
BEAT
Report
-2.3%
aurinia pharmaceuticals inc - common shares
11/4/2025
06:00 am
auph
aurinia pharmaceuticals inc - common shares
BEAT
Report
5.7%
aurinia pharmaceuticals inc - common shares
7/31/2025
06:00 am
auph
aurinia pharmaceuticals inc - common shares
MISS
Report
-2.6%
aurinia pharmaceuticals inc - common shares
5/12/2025
06:00 am
auph
aurinia pharmaceuticals inc - common shares
BEAT
Report
-5.1%
aurinia pharmaceuticals inc - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/3
05:35 pm
auph
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: TANG KEVIN
Medium
Report
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: TANG KEVIN
3/3
05:30 pm
auph
Form SCHEDULE 13D/A Aurinia Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
Medium
Report
Form SCHEDULE 13D/A Aurinia Pharmaceuticals Filed by: TANG CAPITAL MANAGEMENT LLC
3/3
04:18 pm
auph
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: Miller Joseph M
Medium
Report
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: Miller Joseph M
3/3
04:18 pm
auph
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: Greenleaf Peter
Medium
Report
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: Greenleaf Peter
3/3
04:18 pm
auph
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: Donley Matthew Maxwell
Medium
Report
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: Donley Matthew Maxwell
3/3
04:18 pm
auph
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: Robertson Stephen P.
Medium
Report
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: Robertson Stephen P.
3/3
04:18 pm
auph
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: Keenan Greg
Medium
Report
Form 4 Aurinia Pharmaceuticals For: Feb 27 Filed by: Keenan Greg
2/26
06:08 am
auph
Form 10-K Aurinia Pharmaceuticals For: Dec 31
Medium
Report
Form 10-K Aurinia Pharmaceuticals For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/9
Form SC 13D/A Aurinia Pharmaceuticals Filed by: ILJIN SNT Co., Ltd.
13.5%
12/10 Form 6-K Aurinia Pharmaceuticals For: Dec 10 11.7%
9/9 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is now covered by analysts at Citigroup Inc. They set an "outperform" rating and a $14.00 price target on the stock. 10.3%
11/28 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.8%
12/3 Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference 7.1%
3/19 Form 6-K Aurinia Pharmaceuticals For: Mar 18 6.4%
10/15 Does The Aurinia Pharmaceuticals Inc. (TSE:AUP) Share Price Fall With The Market? [Yahoo! Finance News] 6.1%
4/20 Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors 5.4%
12/4 Form 6-K Aurinia Pharmaceuticals For: Dec 03 4.9%
12/10 Form SC 13D/A Aurinia Pharmaceuticals Filed by: ILJIN SNT Co., Ltd. 4.6%
12/10 Form 6-K Aurinia Pharmaceuticals For: Dec 10 11.7%
9/9 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is now covered by analysts at Citigroup Inc. They set an "outperform" rating and a $14.00 price target on the stock. 10.3%
11/28 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.8%
12/3 Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference 7.1%
3/19 Form 6-K Aurinia Pharmaceuticals For: Mar 18 6.4%
10/15 Does The Aurinia Pharmaceuticals Inc. (TSE:AUP) Share Price Fall With The Market? [Yahoo! Finance News] 6.1%
4/20 Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors 5.4%
12/4 Form 6-K Aurinia Pharmaceuticals For: Dec 03 4.9%
12/10 Form SC 13D/A Aurinia Pharmaceuticals Filed by: ILJIN SNT Co., Ltd. 4.6%
TOP News Decliners
10/10
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating.
-13.4%
3/16 Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis -12.3%
3/5 Aurinia Pharmaceuticals' (AUPH) CEO Peter Greenleaf on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -10.4%
3/11 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -8.3%
3/12 Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative -6.7%
8/6 Aurinia Pharmaceuticals, Inc.'s (AUPH) CEO Peter Greenleaf on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.6%
2/22 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.3%
3/17 Form 6-K Aurinia Pharmaceuticals For: Mar 17 -5.5%
2/25 Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team -5.4%
12/2 Aurinia Pharmaceuticals Inc.'s (TSE:AUP) Shift From Loss To Profit [Yahoo! Finance News] -5.3%
3/16 Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis -12.3%
3/5 Aurinia Pharmaceuticals' (AUPH) CEO Peter Greenleaf on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -10.4%
3/11 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -8.3%
3/12 Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative -6.7%
8/6 Aurinia Pharmaceuticals, Inc.'s (AUPH) CEO Peter Greenleaf on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.6%
2/22 Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.3%
3/17 Form 6-K Aurinia Pharmaceuticals For: Mar 17 -5.5%
2/25 Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team -5.4%
12/2 Aurinia Pharmaceuticals Inc.'s (TSE:AUP) Shift From Loss To Profit [Yahoo! Finance News] -5.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: